Literature DB >> 19597000

Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis.

Albert Quintana1, Marcus Müller, Ricardo F Frausto, Raquel Ramos, Daniel R Getts, Elisenda Sanz, Markus J Hofer, Marius Krauthausen, Nicholas J C King, Juan Hidalgo, Iain L Campbell.   

Abstract

IL-6 is crucial for the induction of many murine models of autoimmunity including experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. To establish the role of site-specific production of IL-6 in autoimmunity, we examined myelin oligodendrocyte glycoprotein immunization-induced EAE in transgenic mice (GFAP-IL6) with IL-6 production restricted to the cerebellum. Myelin oligodendrocyte glycoprotein-immunized (Mi-) GFAP-IL6 mice developed severe ataxia but no physical signs of spinal cord involvement, which was in sharp contrast to Mi-wild type (WT) animals that developed classical EAE with ascending paralysis. Immune pathology and demyelination were nearly absent from the spinal cord, but significantly increased in the cerebellum of Mi-GFAP-IL6 mice. Tissue damage in the cerebellum in the Mi-GFAP-IL6 mice was accompanied by increased total numbers of infiltrating leukocytes and increased proportions of both neutrophils and B-cells. With the exception of IL-17 mRNA, which was elevated in both control immunized and Mi-GFAP-IL6 cerebellum, the level of other cytokine and chemokine mRNAs were comparable with Mi-WT cerebellum whereas significantly higher levels of IFN-gamma and TNF-alpha mRNA were found in Mi-WT spinal cord. Thus, site-specific production of IL-6 in the cerebellum redirects trafficking away from the normally preferred antigenic site the spinal cord and acts as a leukocyte "sink" that markedly enhances the inflammatory cell accumulation and disease. The mechanisms underlying this process likely include the induction of specific chemokines, activation of microglia, and activation and loss of integrity of the blood-brain barrier present in the cerebellum of the GFAP-IL6 mice before the induction of EAE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597000     DOI: 10.4049/jimmunol.0900242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  Control of autoimmune CNS inflammation by astrocytes.

Authors:  Veit Rothhammer; Francisco J Quintana
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

2.  Heterogeneity versus homogeneity of multiple sclerosis.

Authors:  Fumitaka Sato; Nicholas E Martinez; Seiichi Omura; Ikuo Tsunoda
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

3.  Deficiency of Socs3 leads to brain-targeted EAE via enhanced neutrophil activation and ROS production.

Authors:  Zhaoqi Yan; Wei Yang; Luke Parkitny; Sara A Gibson; Kevin S Lee; Forrest Collins; Jessy S Deshane; Wayne Cheng; Amy S Weinmann; Hairong Wei; Hongwei Qin; Etty N Benveniste
Journal:  JCI Insight       Date:  2019-04-02

4.  Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ.

Authors:  Manohar B Mutnal; Shuxian Hu; Morgan R Little; James R Lokensgard
Journal:  J Neurovirol       Date:  2011-07-29       Impact factor: 2.643

Review 5.  Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Authors:  M J Hofer; I L Campbell
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

6.  Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.

Authors:  Yudong Liu; Andrew T Holdbrooks; Patrizia De Sarno; Amber L Rowse; Lora L Yanagisawa; Braden C McFarland; Laurie E Harrington; Chander Raman; Steffanie Sabbaj; Etty N Benveniste; Hongwei Qin
Journal:  J Immunol       Date:  2013-12-09       Impact factor: 5.422

Review 7.  Transgenic models for cytokine-induced neurological disease.

Authors:  Iain L Campbell; Markus J Hofer; Axel Pagenstecher
Journal:  Biochim Biophys Acta       Date:  2009-10-14

Review 8.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

9.  Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis.

Authors:  A Uzawa; M Mori; J Taniguchi; S Masuda; M Muto; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

10.  Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis.

Authors:  A Uzawa; M Mori; J Taniguchi; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.